Clinical Efficacy of Low-Dose Venetoclax Combinated with Posaconazole in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments Guided by Venetoclax Blood Concentration

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054356

Enrollment

Unknown

Registered

2021-12-15

Start date

2022-01-01

Completion date

Unknown

Last updated

2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukemia

Interventions

Experimental group:oral venetoclax 100mg/d combined with posaconazole200mg tid

Control group:oral venetoclax 400mg/d

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Frail patients who cannot tolerate standard chemotherapy or who have relapsed or refractory acute myeloid leukemia over the age of 18.

Exclusion criteria

Exclusion criteria: 1. Pregnant patients; 2. Drug intolerance or disobedience to medication instructions; 3. Patients with severe abnormal liver function, renal function and cardiac function; 4. Persons with active tuberculosis or HIV infection.

Design outcomes

Primary

Measure	Time frame
Blood concentration;Dosage;Clinical index;	—

Countries

China

Contacts

Public ContactTan Jing

Chengdu Third People's Hospital

79468064@qq.com+86 28 61318717

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026